Anti-inflammatory treatments targeting IL-6 and IL-1, as well as hemoperfusion techniques, have shown evidence of utility in severe COVID-19, suggesting an exacerbated inflammatory response partly mediates severity [8,9,10]. Here, IL1B is linked to COVID-19.